The pipeline for asthma therapeutics is expected to experience a positive trend in the future, the increase is mainly attributable to decreasing air quality. The prevalence of asthma is increasing globally due to the factors including environmental factors, genetic factors, air pollution, less physical activity and smoking. These factors contribute immensely in driving the pipeline analysis for asthma. According to World Health Organization, around 235 million people suffered from asthma, in 2013. Asthma related deaths occurs more commonly in low and lower middle income countries. Asthma is a very common disease and the treatment options available for the same are expensive. It has been also notes that the disease is more prevalent in women as compared to men.
Asthma is a chronic disease that involves inflammation of bronchial tubes. Bronchial tubes allow air to pass through the lungs and when the lungs get inflamed muscles tend to become stiff, resulting in various symptoms that might be experienced by the patient. The inflammation of bronchial tubes affects the air passage which results in the occurrence of symptoms including breath shortening, wheezing, coughing and chest congestion. These symptoms are usually very active during physical activities such as exercising, walking and running. People with family history of asthma have more chances to develop asthma. There is no cure of asthma, but various treatment options can help to improve the quality of life of patient. Along with the common symptoms of asthma, pattern of symptoms occurrence is also important during diagnosis. Patterns usually include during exercise, during particular season and morning or night. Asthma can be diagnosed by analysing the patient’s family history and certain breathing tests such as spirometry. Asthma cannot be cured but the disease can be dealt with its proper management. . There are certain marketed drugs that are used in the form of inhalation for managing asthma include inhaled corticosteroids, budesonide, mometasone, ciclesonide, flunisolide and beclomethasone.
Novartis AG is in the process of developing a drug by the name QAW039 for the treatment of asthma. QAW039 is a small molecule that acts as prostaglandin D2 receptor antagonists, which is in the Phase III stage of development. AstraZeneca plc with Kyowa Hakko Kirin is currently developing Benralizumab, which is in Phase III stage of clinical trial. Benralizumab is a monoclonal antibody which is an interleukin 5 receptor antagonists. Boehringer Ingelheim GmbH is in the process of developing BI-655066 for the treatment of asthma. It is currently in Phase II stage of development and acts as a monoclonal antibody that inhibits interleukin-23 subunit p19. SolAeroMed Inc. is developing S-1226, which is in Phase II stage of development. It is a small molecule and acts as a cell membrane permeability enhancer. Regeneron Pharmaceuticals, Inc. is in the process of developing REGN3500 which is a monoclonal antibody and modulates interleukin 1 receptor. RP 3128 is being developed by Rhizen Pharmaceuticals SA for the treatment of asthma. It is in Phase I stage of development inhibiting ORAI1 protein.
Some of the companies having a pipeline of asthma therapeutics include Regeneron Pharmaceuticals, Inc., Novartis AG, Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc, AstraZeneca plc, Merck Sharp & Dohme Corp., Mundipharma Research Limited, Actavis Inc., Sanofi, AbbVie, Inc., Boehringer Ingelheim GmbH, Genentech, Inc., Rhizen Pharmaceuticals SA